Loading company…
UCB's Neurology and Allergy Business develops treatments for nervous and immune system conditions.
Based in China, UCB's Neurology and Allergy Business develops drugs and therapies for neurology, immunology, and related conditions. In August 2024, CBC Group and Mubadala Investment Company agreed to acquire the business from UCB for USD 680 million in cash.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at UCB's Neurology and Allergy Business? This is my company